Bruker Co. (NASDAQ:BRKR) Stock Holdings Lessened by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA cut its stake in Bruker Co. (NASDAQ:BRKR - Free Report) by 14.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,458,374 shares of the medical research company's stock after selling 903,164 shares during the period. Massachusetts Financial Services Co. MA owned 3.61% of Bruker worth $376,955,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Covestor Ltd raised its holdings in Bruker by 139.1% in the first quarter. Covestor Ltd now owns 361 shares of the medical research company's stock valued at $34,000 after acquiring an additional 210 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in Bruker by 120.4% in the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company's stock valued at $25,000 after acquiring an additional 218 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Bruker by 115.3% during the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company's stock worth $46,000 after purchasing an additional 354 shares during the period. Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Bruker during the second quarter worth $52,000. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Bruker by 40.7% during the first quarter. EverSource Wealth Advisors LLC now owns 858 shares of the medical research company's stock worth $81,000 after purchasing an additional 248 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Price Performance

Shares of NASDAQ:BRKR traded up $0.85 during trading hours on Friday, hitting $57.07. 2,079,870 shares of the company's stock traded hands, compared to its average volume of 1,105,259. Bruker Co. has a 52 week low of $48.07 and a 52 week high of $94.86. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66. The company's fifty day simple moving average is $61.63 and its two-hundred day simple moving average is $64.77. The company has a market cap of $8.65 billion, a price-to-earnings ratio of 27.44, a price-to-earnings-growth ratio of 2.31 and a beta of 1.20.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. During the same quarter last year, the business posted $0.74 EPS. The business's revenue for the quarter was up 16.4% on a year-over-year basis. As a group, equities analysts anticipate that Bruker Co. will post 2.4 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Monday, December 2nd will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date of this dividend is Monday, December 2nd. Bruker's dividend payout ratio is presently 9.62%.

Analysts Set New Price Targets

A number of brokerages have weighed in on BRKR. TD Cowen dropped their target price on shares of Bruker from $72.00 to $70.00 and set a "hold" rating on the stock in a report on Wednesday, November 6th. Wells Fargo & Company dropped their target price on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating on the stock in a report on Wednesday, November 6th. Wolfe Research lowered shares of Bruker from an "outperform" rating to a "peer perform" rating in a research report on Monday, September 30th. Citigroup lowered their price target on shares of Bruker from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. Finally, Barclays lowered their price target on shares of Bruker from $75.00 to $69.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Bruker currently has an average rating of "Moderate Buy" and an average target price of $79.36.

Insider Buying and Selling at Bruker

In other news, CEO Frank H. Laukien acquired 100,000 shares of Bruker stock in a transaction on Monday, November 18th. The stock was bought at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the purchase, the chief executive officer now owns 38,439,563 shares of the company's stock, valued at $1,927,359,688.82. This represents a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 28.30% of the company's stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.